Anavex Life Sciences (AVXL) Payables (2011 - 2025)
Anavex Life Sciences (AVXL) posted Payables of $2.6 million for Q4 2025, down 37.89% sequentially from $4.2 million in Q3 2025, and down 42.22% YoY from $4.6 million in Q4 2024.
Anavex Life Sciences (AVXL) Payables (2011 - 2025) Analysis & Trends
Anavex Life Sciences has reported Payables for 15 years, with the latest figure at $2.6 million in Q4 2025.
- Quarterly Payables fell 42.22% year-over-year to $2.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.6 million (down 42.22% YoY) and the FY2025 annual result came in at $4.2 million, down 55.86% from the prior year.
- Payables retreated to $2.6 million in Q4 2025 per AVXL's latest filing, from $4.2 million in the prior quarter.
- Over five years, Payables peaked at $9.6 million in Q3 2024 and troughed at $2.3 million in Q1 2025.
- A 5-year average of $4.4 million and a median of $4.2 million in 2021 frame the typical range for Payables.
- The sharpest annual moves came in 2023 and 2025: Payables soared 138.68% in 2023, then plunged 55.86% in 2025.
- Over 5 years, Payables stood at $4.6 million in 2021, then gained by 14.1% to $5.3 million in 2022, then declined by 18.84% to $4.3 million in 2023, then climbed by 6.41% to $4.6 million in 2024, then sank by 42.22% to $2.6 million in 2025.
- According to Business Quant data, Payables over the past three periods registered $2.6 million, $4.2 million, and $6.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | 2.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.64 Mn |
| Sep 30, 2025 | 4.25 Mn |
| Jun 30, 2025 | 6.74 Mn |
| Mar 31, 2025 | 2.30 Mn |
| Dec 31, 2024 | 4.57 Mn |
| Sep 30, 2024 | 9.63 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Mar 31, 2024 | 3.73 Mn |
| Dec 31, 2023 | 4.29 Mn |
| Sep 30, 2023 | 4.32 Mn |
| Jun 30, 2023 | 4.15 Mn |
| Mar 31, 2023 | 6.28 Mn |
| Dec 31, 2022 | 5.29 Mn |
| Sep 30, 2022 | 3.83 Mn |
| Jun 30, 2022 | 3.13 Mn |
| Mar 31, 2022 | 2.63 Mn |
| Dec 31, 2021 | 4.63 Mn |
| Sep 30, 2021 | 4.74 Mn |
| Jun 30, 2021 | 4.18 Mn |
| Mar 31, 2021 | 3.66 Mn |